The aging lung: microenvironment, mechanisms, and diseases

Yanmei Wang, Xuewen Huang, Guo‐Feng Luo, Yunying Xu, Xiqian Deng, Yumeng Lin, Zhanzhan Wang, Shuwei Zhou, Siyu Wang, Hao Chen, Tao Tao, Lei He, Yang Lu-chuan, Li Yang, Yutong Chen, Jin Zi, Chengshi He, Zhongyu Han, Xiaohong ZhangFrontiers in Immunology 2024 · DOI

Abstract

With the development of global social economy and the deepening of the aging population, diseases related to aging have received increasing attention. The pathogenesis of many respiratory diseases remains unclear, and lung aging is an independent risk factor for respiratory diseases. The aging mechanism of the lung may be involved in the occurrence and development of respiratory diseases. Aging-induced immune, oxidative stress, inflammation, and telomere changes can directly induce and promote the occurrence and development of lung aging. Meanwhile, the occurrence of lung aging also further aggravates the immune stress and inflammatory response of respiratory diseases; the two mutually affect each other and promote the development of respiratory diseases. Explaining the mechanism and treatment direction of these respiratory diseases from the perspective of lung aging will be a new idea and research field. This review summarizes the changes in pulmonary microenvironment, metabolic mechanisms, and the progression of respiratory diseases associated with aging.

Introduction

As the global population ages, respiratory diseases have become a leading cause of morbidity and mortality. While it is well-established that elderly patients experience worse clinical outcomes, the specific biological mechanisms driving this vulnerability have historically been fragmented across different sub-fields. This review addresses the gap between chronological aging and the molecular pathogenesis of lung disease, arguing that lung aging is an independent risk factor that fundamentally alters the "soil"—the pulmonary microenvironment—in which diseases like Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), and Idiopathic Pulmonary Fibrosis (IPF) take root.

Methodological Synthesis

This comprehensive review synthesizes findings from a wide array of high-tech modalities to map the aging lung landscape:

  • Single-cell RNA sequencing (scRNA-seq): Identifying over 40 distinct cell types in the lung and tracking their transcriptional shifts over time.
  • Proteomics and Microarrays: Monitoring changes in the extracellular matrix (ECM) and the Senescence-Associated Secretory Phenotype (SASP).
  • Imaging: Utilizing light and electron microscopy to observe structural degradation at the alveolar level.
  • Clinical Data Synthesis: Correlating physiological declines, such as FEV1 and Vital Capacity, with molecular markers of aging.

Key Insights and Pathological Mechanisms

The "Senile Lung" and Alveolar Integrity

The paper distinguishes the "senile lung" (normal aging) from emphysema. While aging involves terminal airspace enlargement, it lacks the overt alveolar wall destruction seen in disease. However, it creates a "pre-diseased" state where Alveolar Epithelial Type II cells (AEC2s)—the lung's stem cells—lose their repair fidelity. This senescence prevents the lung from effectively healing after minor insults.

Comparison of normal lung microenvironment versus the acute phase of respiratory distress, illustrating the accumulation of inflammatory factors and cellular debris.

Mitochondrial Dysfunction and Inflammaging

Aging mitochondria leak self-DNA (mtDNA) into the cytoplasm, acting as a Damage-Associated Molecular Pattern (DAMP). This triggers the cGAS-STING pathway, fueling chronic, low-grade inflammation known as "inflammaging." Furthermore, senescent cells act as metabolically active "factories," producing a cocktail of pro-inflammatory cytokines and proteases (SASP) that degrade neighboring healthy tissue.

Immunosenescence

A critical factor in elderly vulnerability is the decline in alveolar macrophage phagocytosis. As the lung's primary "janitors" become less efficient at clearing pathogens and debris, the risk of severe infection, such as pneumonia and sepsis, increases significantly.

Clinical Results and Functional Decline

  • Structural and Functional Loss: Total alveolar area drops from approximately 70 m² in one's 30s to 60 m² by one's 70s, representing a loss of roughly 2.5 m² per decade. Correspondingly, Vital Capacity (VC) decreases by approximately 200 ml every decade starting from age 20.
  • Molecular Synergy in Disease: In COPD, the deficiency of the anti-aging protein Klotho makes the lung significantly more sensitive to oxidative stress from external factors like cigarette smoke.
  • Therapeutic Frontiers: The review highlights Senolytics (e.g., Dasatinib and Quercetin) and mTOR inhibitors (e.g., Rapamycin) as promising agents that have restored physical function in fibrotic lung models.

Future Directions and Limitations

While mechanistic data from rodent models is robust, there is a critical need for longitudinal human studies to validate these pathways. Furthermore, chronological age is often a poor indicator of lung health; future research must focus on developing "immune aging" scores or biomarkers to better predict disease risk. Finally, the clinical translation of "anti-aging" drugs remains a hurdle, requiring rigorous safety and efficacy testing in elderly populations with multiple comorbidities.

Summary updated

Abstract

With the development of global social economy and the deepening of the aging population, diseases related to aging have received increasing attention. The pathogenesis of many respiratory diseases remains unclear, and lung aging is an independent risk factor for respiratory diseases. The aging mechanism of the lung may be involved in the occurrence and development of respiratory diseases. Aging-induced immune, oxidative stress, inflammation, and telomere changes can directly induce and promote the occurrence and development of lung aging. Meanwhile, the occurrence of lung aging also further aggravates the immune stress and inflammatory response of respiratory diseases; the two mutually affect each other and promote the development of respiratory diseases. Explaining the mechanism and treatment direction of these respiratory diseases from the perspective of lung aging will be a new idea and research field. This review summarizes the changes in pulmonary microenvironment, metabolic mechanisms, and the progression of respiratory diseases associated with aging.
BibTeX
@inproceedings{wang2024aging,
  author = {Yanmei Wang and Xuewen Huang and Guo‐Feng Luo and Yunying Xu and Xiqian Deng and Yumeng Lin and Zhanzhan Wang and Shuwei Zhou and Siyu Wang and Hao Chen and Tao Tao and Lei He and Yang Lu-chuan and Li Yang and Yutong Chen and Jin Zi and Chengshi He and Zhongyu Han and Xiaohong Zhang},
  title = {{The aging lung: microenvironment, mechanisms, and diseases}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1383503},
}
Figure